Lilly’s $7.8B Centessa Bet Signals a New M&A Playbook: Buy the Mechanism, Not the Molecule
Lilly's $7.8B Centessa acquisition, approved by UK High Court on June 22, reveals Big Pharma's new M&A logic: own...
Rare Neurology
Lilly's $7.8B Centessa acquisition, approved by UK High Court on June 22, reveals Big Pharma's new M&A logic: own...